

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18749	
In Re Application Of: Raymond J. Steptoe, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/527,925	March 16, 2005	Unassigned	23389	Unassigned	8585	
Title: A METHOD OF TREATING AN AUTOIMMUNE DISEASE						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>						
OR						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>						

CE 11/13 11 3:00

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18749

In Re Application of: **Raymond J. Steptoe, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/527,925	March 16, 2005	Unassigned	23389	Unassigned	8585

Title:
A METHOD OF TREATING AN AUTOIMMUNE DISEASE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____	
(Date)	
_____ Signature	
_____ Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____	
January 10, 2006	
(Date)	
_____ Signature of Person Mailing Correspondence	
Frank S. DiGiglio	
_____ Typed or Printed Name of Person Mailing Certificate	

*This certificate may only be used if paying by deposit account.

Signature

Dated: January 10, 2006

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Raymond J. Steptoe, et al.

Examiner: Unassigned

Serial No.: 10/527,925

Art Unit: Unassigned

Filed: March 16, 2005

Docket: 18749

For: A METHOD OF TREATING
AN AUTOIMMUNE DISEASE

Dated: January 10, 2006

Confirmation No.: 8585

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. French M.B. et al., "Transgenic Expression of Mouse Proinsulin II Prevents Diabetes in Nonobese Diabetic Mice", *Diabetes*, 46(1):34-39 (1997), XP-009054095;
2. Pugliese A. et al., "Self-Antigen-Presenting Cells Expressing Diabetes-Associated Autoantigens Exist in Both Thymus and Peripheral Lymphoid Organs", *The Journal of Clinical Investigation*, 107(5):555-564 (2001), XP-002345581; and

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 10, 2006



Frank S. DiGiglio

3. Steptoe R.J. et al., "Autoimmune Diabetes Is Suppressed by Transfer of Proinsulin-Encoding Gr-1+ Myeloid Progenitor Cells That Differentiate In Vivo Into Resting Dendritic Cells", *Diabetes*, 54(2):434-442 (2005), XP-002345582.

The references were cited in a Supplementary Search Report dated October 10, 2005 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Supplementary Search Report. The relevance of the above-identified references has been described in the Supplementary Search Report.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

FSD:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT***(Use several sheets if necessary)***Atty. Docket No. (Optional)**

18749

Application Number

10/527,925

Applicant(s)

Raymond J. Steptoe, et al.

Filing Date

March 16, 2005

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		French M.B. et al., "Transgenic Expression of Mouse Proinsulin II Prevents Diabetes in Nonobese Diabetic Mice", <i>Diabetes</i> , 46(1):34-39 (1997), XP-009054095
		Pugliese A. et al., "Self-Antigen-Presenting Cells Expressing Diabetes-Associated Autoantigens Exist in Both Thymus and Peripheral Lymphoid Organs", <i>The Journal of Clinical Investigation</i> , 107(5):555-564 (2001), XP-002345581
		Steptoe R.J. et al., "Autoimmune Diabetes Is Suppressed by Transfer of Proinsulin-Encoding Gr-1+ Myeloid Progenitor Cells That Differentiate In Vivo Into Resting Dendritic Cells", <i>Diabetes</i> , 54(2):434-442 (2005), XP-002345582

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.